How greed and profit fueled one failed Alzheimer drug
On May 3, 2021, Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for his first injection of an experimental drug called simufilam. Cassava Sciences, a Texas biopharma company, had developed simufilam to treat (and possibly cure) Alzheimer's disease, the most common form of dementia that afflicts tens of millions of people worldwide.
When Matt, 27, first heard about simufilam, 'it sounded exciting,' writes Charles Piller in his new book, 'Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's' (Atria/One Signal Publishers), out now. Rather than simply calming symptoms, simufilam promised 'to slow, stop, or reverse cognitive decline — or for people who have no symptoms, prevent them — by attacking Alzheimer's biochemical cause,' writes Piller.
It was based on a long-debated notion called the 'amyloid hypothesis,' which argued that Alzheimer's is caused by the buildup of the protein amyloid in the brain. 'If true, its removal would lead to a cure,' writes Piller. The discovery was shocking, especially given that it'd been introduced by a small biotech company that previously specialized in opioid painkillers and 'had never taken a drug to market in its fifteen years of existence,' writes Piller. 'Yet it claimed to have discovered a new molecule that stabbed the dark heart of the terrible illness.'
Even in the beginning, Matt Price, a Harvard-trained epidemiologist and global-health specialist, had his doubts. Cassava's theory, which had not yet been validated by independent researchers, 'seemed weird and a bit thin,' Matt told the author.
His concerns would soon be confirmed by a whistleblower, who produced 'convincing evidence that lab studies at the heart of the dominant hypothesis for the cause of Alzheimer's disease might have been based on bogus data,' writes Piller. The amyloid hypothesis wasn't just wrong, but it took valuable resources away from other promising theories on how to treat Alzheimer's. It was just the latest example, writes Piller, 'of the exaggeration, hype, and sheer fakery and fraud that has characterized Alzheimer's research for decades.'
And it's not a problem confined to Alzheimer's research alone. As of this month, at least 55,000 medical and scholarly studies have been retracted, according to the Retraction Watch database from the Center of Scientific Integrity. And it's estimated that there may be as many as several hundred thousand fake studies still circulating and not yet identified. Even when they are exposed, journals are often slow to retract the bogus studies, if it happens at all. It's not just an issue of wasted research dollars. 'It makes people start to distrust the clinical research enterprise,' says Price.
Simufilam began as an experimental drug — code-named PTI-125 — developed by neuroscientists Lindsay Burns and Hoau-Yan Wang. It was designed to target filamin A, which becomes twisted into an abnormal shape and causes inflammation in the brain, promoting the formation of myloid-beta proteins. PTI-125, the researchers suggested, could reverse those terrible effects.
The drug was renamed simufilam in August of 2020, and in preliminary studies, patients started showing improvement after just a month — 'extraordinary for any Alzheimer's trial,' writes Piller. Simufilam began to seem like the holy grail, 'the dream drug that generations of researchers had searched for in vain,' the author writes. By late July 2021, the tiny biopharma company, whose sample size for their simufilam experiments was a minuscule fifty participants, suddenly had a market valuation of $5.4 billion.
The victory was short-lived. On Aug. 18, 2021, just weeks after the company's stock reached record highs, two neuroscientists — Geoffrey Pitt of Weill Cornell Medical College and David Bredt, a former executive at drugmakers Eli Lilly and Johnson & Johnson — submitted a 'citizen petition' to the FDA, asking them to take a closer look at simufilam. Their main concern was that the drug's development 'contained manipulated scientific images,' writes Piller. 'In short, they asserted, the work looked like it had been doctored.'
To help prove their suspicions, they brought in Matthew Schrag, a neurologist and neuroscientist at Vanderbilt University, who would become 'the most important whistleblower in the history of Alzheimer's,' writes Piller. When they asked for Schrag's help, 'my response was, 'You think I'm stupid enough to do that?' ' Schrag told the author. 'Apparently, I was.'
Using ImageJ and MIPAV, software developed and endorsed by the NIH, Schrag carefully studied the images used in the simufilam study. He had a 'seasoned eye for detecting digital manipulation with common software programs,' writes Piller. Almost immediately, he spotted proof of manipulation. 'Schrag saw micrographs — magnifications of microscopic features of brain tissue — that seemed obviously cloned,' writes Piller. 'Yet they were presented as findings for different experimental conditions.'
Schrag worried that he wasn't just uncovering evidence of research misconduct, but something much larger and more ominous. 'How had those problems gone unnoticed for years or even decades?' Piller writes. '[Schrag] wondered nervously: What other Alzheimer's research should be reconsidered with skeptical eyes?'
Schrag had an uphill battle, mostly because 'disproving someone else's experiment can be a death wish in science,' writes Piller. Or as Schrag explained to the author, 'The field is absolutely calibrated to the newest, most interesting, most cutting-edge discovery. It disincentivizes replication at every turn.'
Piller shared Schrag's findings with over a dozen experts, including several top Alzheimer's researchers. While most were hesitant to go on the record saying anything negative about the original research, some — like Donna Wilcock, an Alzheimer's expert at the University of Kentucky who would later become editor of Alzheimer's & Dementia — admitted that several images showed 'shockingly blatant' signs of tampering.
But others, like Dennis Selkoe, a Harvard professor of neurologic diseases and a celebrated Alzheimer's researcher, 'chastised' the author for his criticism of the 'objective evidence' that reducing amyloid in the human brain produces better cognitive outcomes. 'I'm on the right side of history,' argued Selkoe, who Piller accuses of being part of the 'Amyloid Mafia.'
George Perry, a scientist at the University of Texas at San Antonio and editor of the Journal of Alzheimer's Disease, agreed with Piller that many Alzheimer's researchers are too hellbent on being correct. 'The major goal of these people is to win—if it isn't the Nobel Prize, it's God's glory,' Perry told the author. 'To be acknowledged that they really did something great. They don't want the amyloid hypothesis to die, because then they have no legacy.'
Schrag delivered his Cassava dossier to the NIH in 2021, providing 'forensic street cred' to doubts about the research, writes Piller. Two years later, in 2023, a university panel found Hoau-Yan guilty of 'egregious misconduct' because of his work for Cassava. Last September, the company agreed to pay $40 million to the Securities and Exchange Commission (SEC) for misleading investors. And then in November, Cassava acknowledged that simufilam failed to deliver the results they'd expected in a phase 3 clinical trial, and the company would be discontinuing research. Their stock plummeted by more than 80% after the announcement.
Schrag wasn't surprised by the outcome. 'You can cheat to get a paper,' he told the author. 'You can cheat to get a degree. You can cheat to get a grant. You can't cheat to cure a disease. Biology doesn't care.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Atlantic
3 hours ago
- Atlantic
Get Ready to Hear a Lot More About Your Mitochondria
Robert F. Kennedy Jr.'s warning about mitochondria slipped in between the anti-vaccine junk science and the excoriation of pharmaceutical drugs as 'the No. 3 killer in our country.' He was speaking in 2023 to Joe Rogan, elaborating on the dangers of Wi-Fi—which no high-quality scientific evidence has shown to harm anyone's health—and arguing that it causes disease by somehow opening the blood-brain barrier, and by degrading victims' mitochondria. The mention of mitochondria—the tiny structures that generate energy within our cells—was brief. Two years later, mitochondrial health is poised to become a pillar of the MAHA movement, already showing up in marketing for supplements and on podcasts across the 'manosphere.' Casey Means, President Donald Trump's newest nominee for surgeon general, has singled out the organelle as the main casualty of the modern American health crisis. According to Means (who has an M.D. but no active medical license), most of America's chronic ailments can be traced to mitochondrial dysfunction. Should she be confirmed to the post of surgeon general, the American public can expect to hear a lot more about mitochondria. Among scientists, interest and investment in mitochondria have risen notably in the past five years, Kay Macleod, a University of Chicago researcher who studies mitochondria's role in cancer, told me. Mitochondria, after all, perform a variety of crucial functions in the human body. Beyond powering cells, they can affect gene expression, help certain enzymes function, and modulate cell death, Macleod said. When mitochondria are defective, people do indeed suffer. Vamsi Mootha, a mitochondrial biologist based at Massachusetts General Hospital and the Broad Institute, told me that rare genetic defects (appearing in about one in 4,300 people) can cause the organelles to malfunction, leading to muscle weakness, heart abnormalities, cognitive disability, and liver and kidney problems. Evidence also suggests that defects in mitochondria directly contribute to symptoms of Parkinson's disease, and could be both a cause and an effect of type 2 diabetes. Other conditions' links to mitochondria are blurrier. Researchers see aberrant mitochondria in postmortem biopsies of patients with illnesses such as Alzheimer's, cancer, and fatty-liver disease, Mootha said; whether those damaged mitochondria cause or result from such conditions is not yet clear. But according to Good Energy, the book Means published last year with a top MAHA adviser—her brother, Calley—mitochondrial dysfunction is a veritable plague upon the United States, responsible for both serious illness and everyday malaise. In their view, modern Western diets and lifestyles wreck countless Americans' metabolic health: Every time you drink unfiltered water or a soda, or feel the stress of mounting phone notifications, you hurt your mitochondria, they say, triggering an immune response that in turn triggers inflammation. (Damaged mitochondria really can cause inflammation, Macleod said.) This chain of events, the Meanses claim, can be blamed for virtually every common chronic health condition: migraines, depression, infertility, heart disease, obesity, cancer, and more. (Casey Means did not respond to requests for comment; reached by email, Calley did not respond to my questions about mitochondria, but noted, 'There is significant scientific evidence that healthy food, exercise and sleep have a significant impact on reversing chronic disease.') Good Energy follows a typical wellness playbook: using a mixture of valid and dubious research to pin a slew of common health problems on one overlooked element of health—and advertising a cure. Among the culprits for our mitochondrial ravaging, according to the Meanses, are poor sleep, medications, ultraprocessed foods, seed oils, too many calories, and too few vitamins, as well as chronically staying in comfortable ambient temperatures. The Means siblings therefore recommend eschewing refined sugar in favor of leafy greens, avoiding nicotine and alcohol, frequenting saunas and cold plunges, getting seven to eight hours of uninterrupted sleep a night, and cleansing your life of environmental toxins. Some studies indeed suggest that mitochondrial function is linked with sleep and temperature, but they've all been conducted on cell cultures, organoids, or mice. According to Macleod, evidence suggests that diet, too, is likely important. But only one lifestyle intervention— exercise —has been definitively shown to improve mitochondrial health in humans. The Meanses are riding a wave of interest in mitochondrial health in the wellness world. Earlier this year, the longevity influencer Bryan Johnson and the ivermectin enthusiast Mel Gibson both endorsed the dye methylene blue for its power to improve mitochondrial respiration; Kennedy was filmed slipping something that looks a lot like methylene blue into his drink. (Kennedy did not respond to a request for comment; the FDA has approved methylene blue, but only as a treatment for the blood disease methemoglobinemia.) AG1, formerly known as Athletic Greens, formulates its drinkable vitamins for mitochondrial health. Even one laser-light skin treatment promises to 'recharge failing mitochondria.' The enzyme CoQ10 is popular right now as a supplement for mitochondrial function, as is NAD, a molecule involved in mitochondria's production of energy. NAD IV drips are especially beloved by celebrities such as Gwyneth Paltrow, Kendall Jenner, and the Biebers. These supplements are generally thought to be safe, and some preliminary research shows that NAD supplementation could help patients with Parkinson's or other neurodegenerative diseases, and that CoQ10 could benefit people with mitochondrial disorders. Patients whose symptoms are clearly caused or made worse by deficiencies in a specific vitamin, such as thiamine, can benefit from supplementing those vitamins, Mootha said. But little research explores how these supplements might affect healthy adults. In Good Energy, as well as on her website and in podcast appearances, Casey Means promotes a number of supplements for mitochondrial health. She also recommends that people wear continuous glucose monitors—available from her company, Levels Health, for $184 a month—to help prevent overwhelming their mitochondria with too much glucose. (According to Macleod, glucose levels are only 'a very indirect measure' of mitochondrial activity.) As with so many problems that wellness influencers harp on, the supposed solution to this one involves buying products from those exact same people. At best, all of this attention to mitochondria could lead Americans to healthier habits. Much of the advice in Good Energy echoes health recommendations we've all heard for decades; getting regular exercise and plenty of fiber is good guidance, regardless of anyone's reasons for doing so. Switching out unhealthy habits for healthy ones will likely even improve your mitochondrial health, Jaya Ganesh, a mitochondrial-disease expert at Icahn School of Medicine at Mount Sinai, told me. After all, 'if you consistently beat your body up with unhealthy habits, everything is going to fall sick,' Ganesh said. But the mitochondrial approach to wellness carries risks, too. For patients with genetically caused mitochondrial disease, lifestyle changes might marginally improve some symptoms, Ganesh said, but attempting to cure such conditions with supplements and a healthy diet alone could be dangerous. Means also calls out medications—including antibiotics, chemotherapy, antiretrovirals, statins, and high-blood-pressure drugs—for interfering with mitochondria. Macleod told me that statins really do affect mitochondria, as do some antibiotics. (The latter makes sense: Mitochondria are thought to have evolved from bacteria more than a billion years ago.) That's no reason, though, to avoid any of these medications if a doctor has determined that you need them. And yet, a whole chapter of Good Energy is dedicated to the idea that readers should mistrust the motives of their doctors, who the authors say profit by keeping Americans sick. The book is less critical of the ways the wellness industry preys on people's fears. Zooming in on mitochondria might offer a reassuringly specific and seemingly scientific explanation of the many real ills of the U.S. population, but ultimately, Means and MAHA are only helping obscure the big picture.
Yahoo
4 hours ago
- Yahoo
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager's website at starting at 7:00 a.m. ET on June 17, 2025. The on-demand webcast will be archived on the Company's website for at least 30 days. About Voyager TherapeuticsVoyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. ContactsTrista Morrison, tmorrison@ Investors: Sarah McCabe, smccabe@ Brooke Shenkin, brooke@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Axios
5 hours ago
- Axios
1 in 10 Hoosiers over 65 has Alzheimer's
Nearly 11% of Hoosiers over 65 are living with Alzheimer's — more than 121,300 people — according to 2020 data shared in a new Alzheimer's Association report. Why it matters: More than 7 million American seniors now live with Alzheimer's, the highest number ever recorded, but addressing cognitive decline early can help stave off the disease. By the numbers: Almost two-thirds of Americans with Alzheimer's are women, per data cited in the report. Risk increases with age: 5.1% of people ages 65–74 have it, while a third of people 85 and older have it, per the report. Zoom in: Indiana's elderly population is expected to grow rapidly in the coming years, according to projections from the Indiana Business Research Center at Indiana University's Kelley School of Business. One in every five Hoosiers (over 966,000 people) will be 65 or older by 2030. Marion County skews a bit younger. The elderly population percentage is here is poised to reach 16.2% in 2030. Stunning stat: The research center says the number of people 65 and up in Indiana will surpass 1.5 million by 2050, a 57% increase from 2015. Threat level: Nearly 18% of Hoosiers 45 and older already have subjective cognitive decline, according to the Alzheimer's Association. And the burden of care is often thrust onto family members. The Alzheimer's Association estimates about 219,000 Indiana caregivers provide unpaid care valued at $6.9 billion for loved ones with the disease. Zoom out: The highest rates of seniors with Alzheimer's are in D.C. (16.8%) and Maryland (12.9%). The lowest is in Alaska (8.8%). What they're saying: "It doesn't surprise me" that Alzheimer's incidence has increased, because the population is aging and "we're becoming more sophisticated in our options for diagnosing and testing for Alzheimer's disease," Lakelyn Eichenberger, a gerontologist and caregiving advocate at Home Instead, tells Axios. With cases climbing and age a key risk factor, early action is critical for managing the disease and accessing new treatments, Eichenberger says. Warning signs to watch for in high-risk age groups: Trouble finding the right word. Difficulty judging distances. Misplacing things and struggling to retrace steps. Between the lines: "If you're seeing patterns of these types of signs over an extended period of time," that could mean it's time to see a doctor about cognitive decline, Eichenberger says.